Impaired Hepatic Function
9 clinical trials · Condition
◉ Watch Impaired Hepatic Function
| Record | Firm | Date |
|---|---|---|
| Study of ALXN2050 in Participants With Hepatic Impairment (NCT05259085) | Alexion Pharmaceuticals, Inc. | 2022-04-07 |
| Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function (NCT04823702) | NGM Biopharmaceuticals, Inc | 2021-04-01 |
| A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function (NCT04136444) | UCB Biopharma S.P.R.L. | 2019-10-28 |
| Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011 (NCT02388620) | Novartis Pharmaceuticals | 2015-03-25 |
| Effect of Hepatic Impairment on LDK378 Pharmacokinetics (NCT01950481) | Novartis Pharmaceuticals | 2014-01-01 |
| A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects (NCT02135302) | Tetraphase Pharmaceuticals, Inc | 2013-10-01 |
| Evaluating Patients With Impaired Hepatic Function (NCT00398424) | Taiho Oncology, Inc. | 2006-02-01 |
Track Impaired Hepatic Function automatically
Every clearance here is in the API, with alerts when new ones post.